Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

Upexi, Inc.

GRVINASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$4.95
$0.35(7.61%)
U.S. Market is Open • 14:29

Upexi, Inc. Fundamental Analysis

Upexi, Inc. (GRVI) shows weak financial fundamentals with a PE ratio of -2.42, profit margin of -6.61%, and ROE of -1.20%. The company generates $0.0B in annual revenue with weak year-over-year growth of -67.77%.

Key Strengths

PEG Ratio0.01
Current Ratio2.20

Areas of Concern

ROE-1.20%
Operating Margin-6.24%
Cash Position0.54%
We analyze GRVI's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -673.8/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-673.8/100

We analyze GRVI's fundamental strength across five key dimensions:

Efficiency Score

Weak

GRVI struggles to generate sufficient returns from assets.

ROA > 10%
-45.92%

Valuation Score

Excellent

GRVI trades at attractive valuation levels.

PE < 25
-2.42
PEG Ratio < 2
0.01

Growth Score

Weak

GRVI faces weak or negative growth trends.

Revenue Growth > 5%
-67.77%
EPS Growth > 10%
-24.43%

Financial Health Score

Moderate

GRVI shows balanced financial health with some risks.

Debt/Equity < 1
4.36
Current Ratio > 1
2.20

Profitability Score

Weak

GRVI struggles to sustain strong margins.

ROE > 15%
-119.69%
Net Margin ≥ 15%
-6.61%
Positive Free Cash Flow
No

Key Financial Metrics

Is GRVI Expensive or Cheap?

P/E Ratio

GRVI trades at -2.42 times earnings. This suggests potential undervaluation.

-2.42

PEG Ratio

When adjusting for growth, GRVI's PEG of 0.01 indicates potential undervaluation.

0.01

Price to Book

The market values Upexi, Inc. at 6.18 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

6.18

EV/EBITDA

Enterprise value stands at 1.02 times EBITDA. This is generally considered low.

1.02

How Well Does GRVI Make Money?

Net Profit Margin

For every $100 in sales, Upexi, Inc. keeps $-6.61 as profit after all expenses.

-6.61%

Operating Margin

Core operations generate -6.24 in profit for every $100 in revenue, before interest and taxes.

-6.24%

ROE

Management delivers $-1.20 in profit for every $100 of shareholder equity.

-1.20%

ROA

Upexi, Inc. generates $-45.92 in profit for every $100 in assets, demonstrating efficient asset deployment.

-45.92%

Following the Money - Real Cash Generation

Operating Cash Flow

Upexi, Inc. generates limited operating cash flow of $-3.79M, signaling weaker underlying cash strength.

$-3.79M

Free Cash Flow

Upexi, Inc. generates weak or negative free cash flow of $-3.61M, restricting financial flexibility.

$-3.61M

FCF Per Share

Each share generates $-0.20 in free cash annually.

$-0.20

FCF Yield

GRVI converts -13.76% of its market value into free cash.

-13.76%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-2.42

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.007

vs 25 benchmark

P/B Ratio

Price to book value ratio

6.18

vs 25 benchmark

P/S Ratio

Price to sales ratio

4.72

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

4.36

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.20

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.20

vs 25 benchmark

ROA

Return on assets percentage

-0.46

vs 25 benchmark

ROCE

Return on capital employed

-0.61

vs 25 benchmark

How GRVI Stacks Against Its Sector Peers

MetricGRVI ValueSector AveragePerformance
P/E Ratio-2.4229.43 Better (Cheaper)
ROE-119.69%800.00% Weak
Net Margin-661.36%-20145.00% (disorted) Weak
Debt/Equity4.360.30 Weak (High Leverage)
Current Ratio2.204.64 Strong Liquidity
ROA-45.92%-17936.00% (disorted) Weak

GRVI outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Upexi, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

16565.63%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

-57134.38%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-5699.81%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ